Interagency Collaboration for Patient-Centered Antibacterial Drug Development
- 6 August 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (Supplement) , S11-S15
Abstract
This manuscript presents key advances of the Antibacterial Resistance Leadership Group (ARLG) Innovations Task Force, a collaboration focused on improving endpoints for registrational trials of antibacterial drugs, including health-related quality-of-life measures, for common acute infections. This group includes members from the United States Food and Drug Administration, National Institutes of Health, academia, industry, and patient representatives to amplify patient voices and ensure that the endpoints are meaningful to how patients feel, function, and survive.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (UM1AI104681))
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation (CIN 13-410)
- Durham Veterans Affairs Health Care System
This publication has 13 references indexed in Scilit:
- Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial PneumoniaClinical Infectious Diseases, 2023
- Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial DrugsClinical Infectious Diseases, 2023
- Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical TrialsClinical Infectious Diseases, 2022
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Antibacterial Resistance Leadership Group 2.0: Back to BusinessClinical Infectious Diseases, 2021
- Measuring the MeaningfulClinical Infectious Diseases, 2020
- Patients’ Experiences With Staphylococcus aureus and Gram-negative Bacterial Bloodstream Infections: A Qualitative Descriptive Study and Concept Elicitation Phase To Inform Measurement of Patient-reported Quality of LifeClinical Infectious Diseases, 2020
- Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk EvaluationStatistics in Biopharmaceutical Research, 2016
- Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)Clinical Infectious Diseases, 2015
- Linking Clinical Variables With Health-Related Quality of LifeJAMA, 1995